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1. Introduction
The importance of the relationship between the gut 
microbiome and the development of the immune system 
is well recognised (Zheng et al., 2020) and there is 
evidence indicating crosstalk between the gut microbiota 
and the lungs (Angurana and Bansal, 2020). Probiotics 
have demonstrated an antiviral activity against common 
respiratory viruses including influenza, rhinovirus, 
respiratory syncytial virus and coronavirus and their role 
in the management of COVID-19 is gaining attention 
(Baud et al., 2020; d’Ettorre et al., 2020; Tiwari et al., 
2020). A predictive study has estimated that probiotic 
supplementation of the entire US population could 
prevent up to 54.5 million sick days with respiratory tract 
infection, 4.2 million missed work days, over a billion dollars 
expenditure and up to 2.2 million antibiotic prescriptions 
annually (Lenoir-Wijnkoop et al., 2019).
Upper respiratory tract infections (URTIs) are mostly 
viral and comprise approximately 90% of total respiratory 
infections (Marengo et al., 2017). Children are particularly 
susceptible because of their immune immaturity (Feleszko 
et al., 2019) and there is growing evidence to suggest that 
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Abstract
In a double-blind, randomised, parallel-group, placebo-controlled study, healthy school children aged 3-10 years 
received a probiotic based supplement daily for 6 months to assess the impact on the incidence and duration of 
upper respiratory tract infection (URTI) symptoms. The intervention comprised Lab4 probiotic (Lactobacillus 
acidophilus CUL21 and CUL60, Bifidobacterium bifidum CUL20 and Bifidobacterium animalis subsp. lactis CUL34) 
at 12.5 billion cfu/day plus 50 mg vitamin C or a matching placebo. 171 children were included in the analysis (85 
in placebo and 86 in active group). Incidence of coughing was 16% (P=0.0300) significantly lower in the children 
receiving the active intervention compared to the placebo. No significant differences in the incidence rate of other 
URTI symptoms were observed. There was significantly lower risk of experiencing five different URTI related 
symptoms in one day favouring the active group (Risk ratio: 0.31, 95% confidence interval: 0.12, 0.81, P=0.0163). 
Absenteeism from school and the use of antibiotics was also significantly reduced for those in the active group 
(-16%, P=0.0060 and -27%, P=0.0203, respectively). Our findings indicate that six months daily supplementation 
with the Lab4 probiotic and vitamin C combination reduces the incidence of coughing, absenteeism and antibiotic 
usage in 3 to 10 year old children.
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daily supplementation with probiotics or vitamin C may 
play role in the management of URTI in children (Emre et 
al., 2020; Hao et al., 2015; Hemilä and Chalker, 2013; King 
et al., 2014; Vorilhon et al., 2019). Our own pilot study with 
young children (3 to 6 year olds) has highlighted potential 
benefits from 6 months daily supplementation with Lab4 
probiotics plus 50 mg vitamin C (Garaiova et al., 2015). 
The objective of this study was to investigate the impact of 
the same probiotic based intervention on the prevention of 
upper respiratory tract symptoms in a broader population 
of school children aged between 3 and 10 years.
2. Materials and methods
Study design and approval
This was an exploratory multi-centre, double-blind, 
randomised, parallel-group, placebo-controlled study 
(PROCHILD-2). The study was conducted in accordance 
with the principles of the Declaration of Helsinki and 
the protocol was approved by the Ethics Committee of 
Bratislava self-governing region, Slovakia (Ref: 07878/2016-
HF). The study was registered with the ISRCTN registry 
(ISRCTN26587549).
Study population, recruitment and randomisation
A total of 234 children (3-10 years old) were recruited 
from four paediatric health centres/general practices in 
Slovakia. Recruitment started in December 2016 and 
continued until March 2017 (n=90), then paused during 
the late spring and summer seasons, restarted again in 
October 2017 and continued until March 2018 (n=144). 
Paediatric physicians recruited the children either during 
routine preventative visits to a participating study centre 
or through poster advertisements displayed in study centre 
waiting rooms. Children were excluded if they were not 
attending school, were unwell or receiving antibiotics at the 
time of recruitment, receiving probiotic products regularly 
or any medication for stimulation of the immune system; if 
they were sensitive to xylitol/sorbitol. None of the children 
received the flu vaccine prior to or during the study period. 
Written informed consent was obtained from parents or 
legal guardians prior to participation in the study. Eligible 
children were sequentially assigned to the study by the 
paediatric physician and allocated in a 1:1 ratio to either of 
the two arms of the study according to a computer-generated 
random sequence using block randomisation with a block-
size of four and stratified by centre. The randomisation 
was performed by an independent statistician who had no 
contact with the participants. The allocation sequence was 
not available to any member of the research team until the 
databases had been completed and locked.
Study intervention
Children received daily either one chewable tablet 
containing Lactobacillus acidophilus CUL21 (NCIMB 
30156) and CUL60 (NCIMB 30157), Bifidobacterium 
bifidum CUL20 (NCIMB 30153) and Bifidobacterium 
animalis subsp. lactis CUL34 (NCIMB 30172) (Lab4) 
at 1.25×1010 cfu in combination with 50 mg vitamin C 
or an identical looking placebo tablet without the active 
components for 6 months. Interventions were prepared 
by Cultech Ltd., Port Talbot, UK. Parents/guardians were 
instructed to give their children one chewable tablet in 
the morning after breakfast and to avoid administration 
within 2 h of any antibiotic intake. In addition, parents 
were advised to maintain the children’s normal diet and 
lifestyle throughout the study avoiding the consumption of 
any other probiotic drinks and supplements. Compliance 
to the intervention was assessed by monitoring the number 
of unused chewable tablets or from the daily health diaries.
Data collection
At baseline, all children were examined by a paediatric 
physician and background information, including history 
of allergy and any antibiotic and/or regular medication use 
were recorded. Body weight and height were measured 
using a digital weighing and measuring station with 
automatic body mass index calculation (kg/m2, SECA 
764, SECA Deutschland, Hamburg, Germany). During the 
study period, children were examined by a paediatrician at 
prescheduled 2-, 4- and 6-month appointments when the 
parents/guardians were instructed how to complete the daily 
health diaries monitoring the following URTI symptoms 
(based on guidance from the study paediatrician): sneezing, 
sore throat, cough, nasal discharge and nasal congestion. 
In addition, fever, earache, chest wheeze, absenteeism, 
antibiotic and/or other medication use, gastrointestinal 
symptoms (stool consistency, stomach-ache and vomiting), 
physician visits, hospitalisation and intervention compliance 
were recorded by the child’s parents/guardians. Completed 
daily health diaries and unused tablets were collected and 
the intervention for next two months were provided at the 
scheduled visits.
Study endpoints
Primary end points were the incidence and duration of 
URTI symptoms over the 6-month study period. The 
symptoms selected to include as representing the Total 
URTI symptoms were: cough, sore throat, nasal congestion, 
nasal discharge and sneezing. The secondary end points 
included the incidence of absenteeism from school, 
antibiotic usage and gastrointestinal symptoms.
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Statistical analysis
The incidence rate represents the number of episodes of 
each symptom, absenteeism or antibiotic usage divided by 
the number of days in the study and is expressed per 100 
person days. Each distinct episode comprised the number 
of consecutive days with the symptom and each distinct 
episode was separated from another episode by a minimum 
duration of 24 h symptom free. Total URTI symptoms is 
defined as the incidence of symptom episodes comprising 
any one or more of the individual symptoms. The duration 
(mean difference) represents the total number of days 
with the symptom or absenteeism in the group divided by 
number of participants within that group. The incidence 
rates and durations with 95% confidence intervals (CIs) 
were calculated using a generalised linear model (GLM) 
that included treatment as a single predictor. For GLM 
analysis of a continuous endpoint such as duration of URTI 
symptoms, normal distribution and identity link functions 
were used; for GLM analysis of recurrent events (such 
as the number of episodes of URTI symptoms), Poisson 
distribution and log linkg4 functions were used. Continuous 
variables were summarised using number of observations, 
mean (standard deviation), whereas categorical variables 
were summarised by the number and percentage of events. 
Post-hoc covariate-adjusted analysis was performed with 
treatment as study variable and age, gender and history of 
allergy as covariates. A generalised linear model (GLM) 
was used for covariate adjusted analysis. Time-to-event 
for the first symptom in the groups was analysed with the 
Kaplan-Meier method, and significance was assessed by 
the Log-rank Mantel-Cox test (GraphPad Prism, version 
8.2.2, La Jolla, CA, USA). P-values were considered 
statistically significant when less than 0.05. Data analyses 
were performed using SAS® version 9.4 (SAS Institute Inc., 
Cary, NC, USA).
3. Results
Enrolment, baseline characteristics and compliance
The participant flow diagram is shown in Figure 1. Of the 
260 contacted participants, 234 were enrolled between 
December 2016 and March 2018. Six children in the 
placebo group and five children in the active group were 
incorrectly included in the randomisation (did not meet 
the inclusion criteria) and were excluded. Fifteen children 
withdrew shortly after randomisation (Figure 1). A total 
of 37 children were excluded from the analysis; 4 due to 
lost records, 2 due to non-compliance to the protocol, 
21 due to non-authorised treatment usage (vitamin C/
immunostimulants) and 10 due to non-compliance to 
intervention intake (<80%). The proportions of excluded/
withdrawn children were similar in both arms; 31 children 
in active group (26.5%) and 32 children in placebo group 
(27.3%). Thus, the loss of follow-up was assumed to occur 
at random and no analysis adjustment for the loss of follow-
up was made. 171 participants completed the study (85 in 
placebo and 86 in active group).
Compliance to the interventions by those who were 
included in the study was 96.1% and comparable between 
groups. Baseline characteristics of participants are included 
in Table 1.
Upper respiratory tract infection symptoms
Incidence
The incidence rates of individual and total URTI symptoms 
are shown in Table 2. Daily supplementation with the Lab4 
probiotic plus vitamin C significantly reduced the incidence 
rate of coughing (-16%, P=0.0300) and sore throats (-20%, 
P=0.0373) compared to the placebo. There were no 
significant between group differences in the incidence 
rate of any other URTI symptoms. URTI symptoms were 
not reported for six of the children (3 in each group) over 
the study period. The incidence rates of fever, wheezing and 
earache did not differ between groups (Table 2). The results 
from the post-hoc covariate-adjusted analysis are presented 
in Supplementary Tables S1 and S4. The outcomes remain 
similar to the unadjusted analysis with the only exception 
of sore throat.
Time-to-first episode curves for the URTI symptoms are 
shown in Figure 2. There was no between group difference 
in the time-to-first URTI symptom episode irrespective 
of the type of symptom (Figure 2A). However, after 
approximately 10 days supplementation, the time to first 
episode of cough for those in the active group was longer 
than that for the participants in the placebo group and this 
delay in symptom onset persisted over the duration of the 
study (Figure 2B). The median time taken for 50% of the 
children to experience the first episode of coughing was 
53.5 days in the active group – double that of the 27 days 
for the placebo (Figure 2B). For sore throat, the difference 
in timings was 115 days in the active group compared to 
125 days in the placebo (Figure 2C).
The number of total URTI symptoms (cough, sore throat, 
sneezing, nasal discharge and nasal congestion) recorded 
per day for each participant in the active and placebo groups 
has been determined from 1 symptom to 5 symptoms and 
the incidence rates are presented in Table 3. In the active 
group, the incidence rate of those episodes including four or 
five different symptoms on one day was significantly lower 
than for the placebo (-29%, P=0.0278 and -79%, P<0.0001, 
respectively). During the 6-month study period, only 5.8% 
children (5/86) in the active group had all five symptoms on 
one day compared to 18.8% children (16/85) in the placebo 
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Analysed (n=86)
Assessed for eligibility (n=260)
Excluded (n=26)
• Not meeting inclusion criteria/declined
  to participate (n=26)
• Other reasons (n=0)
Randomised (n=234)
Placebo group (n=117)
• Received allocated intervention (n=117)
• Did not receive allocated intervention (n=0)
Active group (n=117)
• Received allocated intervention (n=117)
• Did not receive allocated intervention (n=0)
Enrolment
Allocation
Incorrectly included in randomisation (n=6)
Premature withdrawal:
• Lost to follow up (refusal to continue,
  lost interest with no data provided) (n=6)
• Adverse events (nausea) (n=1)
Excluded from analysis:
• All records lost (n=3)
• Non-compliant with protocol (n=16) 
Incorrectly included in randomisation (n=5)
Premature withdrawal:
• Lost to follow up (refusal to continue,
  lost interest with no data provided) (n=6)
• Adverse events (nausea, stomach ache) (n=2)
Excluded from analysis:
• All records lost (n=1)




Figure 1. Flow diagram of the study.
Table 1. Baseline characteristics of study participants.
Characteristic1 Placebo (n=85) Active (n=86) Total (n=171)
Age, years 6.7±2.0 6.5±2.1 6.6±2.0
Gender, n (%) Girls 48 (56.5%) 35 (40.7%) 83 (48.5%)
Boys 37 (43.5%) 51 (59.3%) 88 (51.5%)
BMI, kg/m2 16.1±2.5 16.4±2.5 16.3±2.5
Girls 15.9±2.1 16.3±2.3 16.1±2.2
Boys 16.4±2.9 16.4±2.7 16.4±2.8
Centre, n (%) Centre 1 47 (55.3%) 46 (53.5%) 93 (54.4%)
Centre 2 19 (22.4%) 13 (15.1%) 32 (18.7%)
Centre 3 12 (14.1%) 17 (19.8%) 29 (17.0%)
Centre 4 7 (8.2%) 10 (11.6%) 17 (9.9%)
Allergy, n (%) Food 0 (0%) 11 (12.8%) 11 (6.4%)
Asthma 3 (3.5%) 2 (2.3%) 5 (2.9%)
Atopic eczema 2 (2.4%) 4 (4.7%) 6 (3.5%)
Hay fever 5 (5.9%) 9 (10.5%) 14 (8.2%)
Other 5 (5.9%) 4 (4.7%) 9 (5.3%)
1 Data are presented as mean ± standard deviation. BMI = body mass index.
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Table 2. Incidence of upper respiratory tract (URTI) and other symptoms.1
Placebo (n=85) Active (n=86) Placebo (n=85) Active (n=86)
URTI symptoms
Cough Total URTI symptoms3
Number of episodes 178 152 Number of episodes 313 330
Incidence rate2 1.18 1.0 Incidence rate2 2.07 2.16
IRR (95% CI) 0.84 (0.72, 0.98) IRR (95% CI) 1.04 (0.93, 1.16)
P-value 0.0300 P-value 0.4592
Sore throat
Number of episodes 102 83
Incidence rate2 0.68 0.54
IRR (95% CI) 0.80 (0.66, 0.99)
P-value 0.0373 Other symptoms
Nasal congestion Fever4
Number of episodes 138 144 Number of episodes 70 64
Incidence rate2 0.91 0.94 Incidence rate2 0.46 0.42
IRR (95% CI) 1.03 (0.87, 1.22) IRR (95% CI) 0.90 (0.71, 1.15)
P-value 0.7132 P-value 0.4079
Nasal discharge Wheezing 
Number of episodes 208 206 Number of episodes 8 5
Incidence rate2 1.38 1.35 Incidence rate2 0.05 0.03
IRR (95% CI) 0.98 (0.85, 1.12) IRR (95% CI) 0.62 (0.28, 1.36)
P-value 0.7597 P-value 0.2322
Sneezing Earache
Number of episodes 138 148 Number of episodes 13 15
Incidence rate2 0.91 0.97 Incidence rate2 0.09 0.10
IRR (95% CI) 1.06 (0.90, 1.25) IRR (95% CI) 1.14 (0.67, 1.93)
P-value 0.4855 P-value 0.6236
1 IRR = incidence rate ratio; CI = confidence interval.
2 Incidence rate per 100 person-day.
3 Total URTI symptoms is defined as the incidence of symptom episodes comprising any one or more of the individual symptoms.
4 Temperature 38 °C or over.
A B C 








































































Figure 2. Kaplan-Meier time to event for the first upper respiratory tract infection (URTI) symptom: (A) any URTI symptom, 
χ2=0.0094, P=0.9227; (B) cough, χ2=1.915, P=0.1664; (C) sore throat, χ2= 0.3054, P=0.5805. The median time to symptom (dotted 
line) was (A) 15 days for the first URTI symptom in the active group and 17 days in the placebo group; (B) 53.5 days for cough in 
the active group and 27 days in the placebo group; (C) 115 days for sore throat in the active group and 125 days in the placebo. 
The statistical significance was calculated by Log-rank Mantel-Cox test.
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group (Risk ratio: 0.31, 95% CI: 0.12, 0.81, P=0.0163). There 
was a significantly higher incidence rate of episodes with 
one symptom (predominantly nasal discharge) in the active 
group compared to the placebo (P=0.0234). The results 
from the post-hoc covariate-adjusted analysis are similar 
(Supplementary Tables S2 and S5).
Duration
The findings for sore throats indicate a 33% reduction in 
the average number of days with sore throats for children 
in the active group compared to the placebo (3.0 vs 4.5 
days per child, mean difference: -1.4 days, 95% CI: -3.0, 0.1, 
P=0.0717). No significant changes in the duration of the 
total URTI and other individual symptoms were observed 
between groups.
The average number of days per episode (episode length) 
of the total URTI symptoms was 5.5 days for the active 
group; significantly shorter than the 6.1 days observed for 
the placebo (mean difference: -0.66 days, 95% CI: -1.29, 
-0.04; P=0.0371). The average number of days per episode 
of cough was also significantly shorter in the active group 
compared to the placebo (4.1 vs 5.3 days per episode, mean 
difference: -1.2 days, 95% CI: -2.0, -0.3; P=0.0083). The 
episode length for the other individual symptoms showed 
no between group differences.
Absenteeism
Overall, there was a 16% significant reduction in the 
incidence rate of absenteeism from school in the Lab4 
probiotic/vitamin C supplemented children compared to 
the placebo (0.0145 vs 0.0174, respectively, P=0.0060, Figure 
3). The result from the post-hoc covariate-adjusted analysis 
were similar (Supplementary Figure S1). The average 
number of days absent from school per child was 8.3 days 
in the active group compared to 9.4 days in the placebo 
(mean difference: -1.1 days, 95% CI: -4.2, 1.9; P=0.4570).
Antibiotic usage
The forest plot in Figure 3 presents the incidence rate ratio 
of antibiotic use (irrespective of the number or type of 
antibiotic). The incidence rate of total antibiotic use in 
the active group was 27% lower than in the control group 
(P = 0.0203). The result from the post-hoc covariate-
adjusted analysis is similar to the unadjusted analysis (-29%, 
P=0.0121, Supplementary Figure S1).
Table 3. Incidence of number of five common upper respiratory 
tract infection (URTI) symptoms.1,2
Number of symptoms Placebo (n=85) Active (n=86)
1 symptom
Number of episodes 269 311
Incidence rate3 1.78 2.04
IRR (95% CI) 1.14 (1.02, 1.28)
P-value 0.0234
2 symptoms
Number of episodes 194 211
Incidence rate3 1.29 1.38
IRR (95% CI) 1.08 (0.94, 1.23)
P-value 0.3033
3 symptoms
Number of episodes 102 94
Incidence rate3 0.68 0.62
IRR (95% CI) 0.91 (0.75, 1.11)
P-value 0.3562
4 symptoms
Number of episodes 50 36
Incidence rate3 0.33 0.24
IRR (95% CI) 0.71 (0.53, 0.96)
P-value 0.0278
5 symptoms
Number of episodes 24 5
Incidence rate3 0.16 0.03
IRR (95% CI) 0.21 (0.10, 0.41)
P-value <0.0001
1 IRR = incidence rate ratio; CI = confidence interval.
2 URTI symptoms included (cough, sore throat, nasal congestion, nasal 
discharge and sneezing). 3 Incidence rate per 100 person-day.
n IRR 95% CI P-value
Absenteeism 85/86 0.84 0.74, 0.95 0.0060
Antibiotics 85/86 0.73 0.57, 0.95 0.0203
IRR (95% CI)
Favours placeboFavours active
0.4 0.6 0.8 1.0 1.2 1.4
Figure 3. Incidence rate ratio (IRR) forest plot of absenteeism and antibiotic usage. CI = confidence interval.
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Additional parameters
In the active group the incidence rate of total paediatric 
physician visits (scheduled/unscheduled) was reduced 
compared to the placebo (IRR: 0.81, 95% CI: 0.69, 0.95, 
P=0.0077). There were significantly less changes in normal 
stool consistency in the active group compared to the 
placebo (IRR: 1.12, 95% CI: 1.07, 1.18, P<0.0001) together 
with a significant reduction in the incidence rate of watery 
stools episodes (IRR: 0.56, 95% CI: 0.45, 0.71, P<0.0001). 
The results from the post-hoc covariate-adjusted analysis 
are similar (Supplementary Table S3 and S6). There were no 
between group differences in incidence of stomach-ache or 
vomiting. Four children were hospitalised during the study 
period (2 placebo/2 active) for illness/reasons unrelated to 
upper respiratory tract infections.
4. Discussion
Daily intake of the probiotic-based supplement resulted 
in a significant reduction in the incidence rate of coughs, 
absenteeism and antibiotic usage over the 6-month study 
period. Children taking the intervention had a 69% lower 
risk of experiencing all five URTI symptoms (cough, sore 
throat, sneezing, nasal discharge and nasal congestion) on 
one day compared to children taking placebo.
Both probiotics and vitamin C have been shown to possess 
immunomodulatory capability (Baud et al., 2020; Carr 
and Maggini, 2017; Maldonado Galdeano et al., 2019). 
The innate immune system provides the host’s first line 
of defence against a viral challenge and involves, in part, 
the production of interleukin (IL)-12 and IL-1β by tissue 
residing immune cells such as macrophages (Arango Duque 
and Descoteaux, 2014). These pro-inflammatory cytokines 
play key roles in the resolution of infection by regulating 
the secretion of chemokines and other cytokines and 
promoting the differentiation, recruitment and activation 
of immune cells (Guo et al., 2019; Rathinam and Fitzgerald, 
2010). In vitro work with the Lab4 probiotic consortium 
has demonstrated enhanced production of IL-12 and IL-
1β by macrophages undergoing simulated viral challenge 
thus indicating the potential to heighten the immune 
response to infection (Davies et al., 2018). Similar in vitro 
findings in macrophages have been observed in response to 
stimulation with Lactobacillus rhamnosus GG (Miettinen 
et al., 2012). Vitamin C is thought to possess virucidal 
properties and has been shown to induce the expression 
of anti-viral interferons during the early stages of viral 
infection (Colunga Biancatelli et al., 2020). The benefits of 
the Lab4 probiotic and low dose vitamin C combination 
on the incidence and duration of URTI symptoms were 
first demonstrated in our PROCHILD study with children 
aged 3 to 6 years, however, no between group differences 
in plasma levels of cytokines were detected although 
blood samples were not taken when the children were 
symptomatic (Garaiova et al., 2015).
In other probiotic multi-strain combination studies, 
beneficial effects on URTIs in children have been observed 
with L. acidophilus NCFM/B. animalis subsp. lactis 
Bi-07 (1×1010 cfu/day) (Leyer et al., 2009) and also L. 
acidophilus/B. bifidum (4×109 cfu/day) (Rerksuppaphol 
and Rerksuppaphol, 2012). Little or no effects were reported 
with B. animalis subsp. lactis BB12 in combination with 
L. rhamnosus GG (2x109 cfu/day) (Laursen et al., 2017) or 
Lactobacillus plantarum HEAL9/Lactobacillus paracasei 
8700:2 (1×109 cfu/day) (Lazou Ahren et al., 2020).
Meta-analysis of vitamin C intervention studies has shown 
that in children supplemented with 200 mg/day or more of 
vitamin C, the duration of URTI was reduced by 14% and 
with higher doses of vitamin C (1 to 2 g/day) achieving 18% 
reduction. Limited evidence exists to support any beneficial 
effects of low vitamin C dose (<200 mg per day) on URTI 
(Hemilä and Chalker, 2013). To the best of our knowledge, 
there is no published evidence by other research groups 
showing beneficial effects for probiotics with vitamin C 
(under 100 mg/day) in the prevention or management of 
upper respiratory tract infection in children. One study 
demonstrated a favourable effect with a herbal preparation 
containing echinacea, propolis and vitamin C (100 mg 
to 150 mg/day) in the management of respiratory tract 
infections in children aged 1-5 years (Cohen et al., 2004). 
Low doses of vitamin C (10-50 mg) were included as a 
component of the placebo in some early vitamin C studies 
(Vorilhon et al., 2019).
Coughing is common in children and is most often caused 
by acute respiratory infection. In a large population-based 
prospective cohort study, 69% of children aged 1 to 18 years 
were reported to have a cough with colds irrespective of age 
(Jurca et al., 2017). In Chinese children (aged 3 to 5 years) 
attending day-care, supplementation with L. acidophilus 
NCFM combined with B. animalis subsp. lactis Bi-07 at a 
dose of 1010 cfu/day for 6 months resulted in the significant 
reduction of the incidence of cough (Leyer et al., 2009). 
Coughing was also reduced in Thai children aged 8-13 
years supplemented with an L. acidophilus/B. bifidum 
combination at a dose of 4×109 cfu/day for 3 months 
(Rerksuppaphol and Rerksuppaphol, 2012). In our study 
with children aged 3 to 10 years, we observed significant 
reductions in the incidence and episode length of coughing 
together with an indication of a delay in the onset of the 
first coughing event suggesting that the active intervention 
might reduce the susceptibility of these children to cough.
In addition, we have observed the improvement in sore 
throats with active intervention, but not in fever, nasal 
congestion/discharge, sneezing, wheezing or earache. 
Other studies with multistrain probiotic interventions 
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have reported reductions in fever and rhinorrhoea 
alongside coughing (Leyer et al., 2009; Rerksuppaphol 
and Rerksuppaphol, 2012). The authors did not evaluate 
the probiotic effect on the incidence of sore throat.
Reduced incidence of URTI can contribute to less absence 
from school for the child and less demand on parents/
guardians and healthcare providers. Our study showed a 
significant reduction in the incidence rate of absenteeism 
with the active intervention in line with other probiotic 
studies (Hatakka et al., 2001; Hojsak et al., 2010; Leyer et 
al., 2009; Rerksuppaphol and Rerksuppaphol, 2012).
Inappropriate antibiotic use for URTIs in children is a 
global issue (Holstiege et al., 2014) and strategies are 
required to minimise the increased spread of antibiotic 
resistance associated with inappropriate usage and any 
potential detrimental impacts on long-term health. It has 
been found that infants and children supplemented with 
probiotics to prevent acute respiratory and gastrointestinal 
tract infections had a 29% lower relative risk of being 
prescribed antibiotics (King et al., 2019). We also observed 
a significant 27% reduction in the incidence of antibiotic 
usage alongside a significantly reduced incidence rate of 
paediatric physician visits.
One of the main strengths of our study is that this is our 
second long-term study with the same probiotic based 
intervention focusing on the prevention of URTI symptoms 
and absenteeism in children but in this case the age range 
was broadened. Moreover, the recruitment of participants 
was performed in four discrete paediatric centres in two 
different cities of south-west Slovakia to minimise any 
single centre limitation and allow better generalisation of 
our findings. On the other hand, we are aware of the lack of 
a formal power calculation due to exploratory nature of the 
study with broader children’s age range. We did not include 
probiotic alone or vitamin C alone study arms as our aim 
was to follow the protocol from our first study where the low 
dose of vitamin C was included to the probiotic intervention 
in response to suggestions made by the paediatricians who 
would be recruiting children for the study (They anticipated 
better parental acceptance to participate in a study with 
vitamin C as a component of the intervention). For future 
studies it would be useful to include an assessment of the 
severity of the symptoms as an additional outcome. It would 
be also interesting to look at the relationship between URTI 
symptoms and the incidence and severity of fever.
Our findings suggest a beneficial impact of supplementation 
with the Lab4 probiotic consortium in combination with 
a low dose vitamin C on the incidence of coughing, 
absenteeism and antibiotic usage in children aged 3 to 
10 years.
Supplementary material
Supplementary material can be found online at https://doi.
org/10.3920/BM2020.0185.
Table S1. Post-hoc covariate adjusted analysis for incidence 
of upper respiratory tract infection and other symptoms 
with treatment as study variable and age, gender and history 
of allergy as covariates.
Table S2. Post-hoc covariate adjusted analysis for incidence 
of number of five common upper respiratory tract infection 
symptoms with treatment as study variable and age, gender 
and history of allergy as covariates.
Table S3. Post-hoc covariate adjusted analysis for incidence 
of paediatric physician visits and stool consistency with 
treatment as study variable and age, gender and history of 
allergy as covariates.
Table S4. Post-hoc covariate adjusted analysis for incidence 
of upper respiratory tract infection and other symptoms 
with treatment as study variable and age, gender and history 
of allergy as covariates (b values and 95% CI).
Table S5. Post-hoc covariate adjusted analysis for incidence 
of number of five common upper respiratory tract infection 
symptoms with treatment as study variable and age, gender 
and history of allergy as covariates (b values and 95% CI).
Table S6. Post-hoc covariate adjusted analysis for incidence 
of paediatric physician visits, stool consistency, absenteeism 
and antibiotic usage with treatment as study variable and 
age, gender and history of allergy as covariates (b values 
and 95% CI).
Figure S1. Post-hoc covariate adjusted analysis for incidence 
rate ratio forest plot of absenteeism and antibiotic usage 
with age, gender and history of allergy as covariates.
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